Cite
Huneycutt E, Board C, Clements JN. Lesinurad, a Selective URAT-1 Inhibitor With a Novel Mechanism in Combination With a Xanthine Oxidase Inhibitor, for Hyperuricemia Associated With Gout. J Pharm Pract. 2017;897190017734427doi: 10.1177/0897190017734427.
Huneycutt, E., Board, C., & Clements, J. N. (2017). Lesinurad, a Selective URAT-1 Inhibitor With a Novel Mechanism in Combination With a Xanthine Oxidase Inhibitor, for Hyperuricemia Associated With Gout. Journal of pharmacy practice, 897190017734427. https://doi.org/10.1177/0897190017734427
Huneycutt, Emily, et al. "Lesinurad, a Selective URAT-1 Inhibitor With a Novel Mechanism in Combination With a Xanthine Oxidase Inhibitor, for Hyperuricemia Associated With Gout." Journal of pharmacy practice vol. (2017): 897190017734427. doi: https://doi.org/10.1177/0897190017734427
Huneycutt E, Board C, Clements JN. Lesinurad, a Selective URAT-1 Inhibitor With a Novel Mechanism in Combination With a Xanthine Oxidase Inhibitor, for Hyperuricemia Associated With Gout. J Pharm Pract. 2017 Jan 01;897190017734427. doi: 10.1177/0897190017734427. Epub 2017 Jan 01. PMID: 28980503.
Copy
Download .nbib